Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 18Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 3Nasopharyngeal Carcinoma 3Recurrence 2Non-Muscle Invasive Bladder Neoplasms 2Lung Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Uterine Neoplasms 1Thromboembolism 1Stomach Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1NSCLC 1Malnutrition 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Locally Advanced Pancreatic Cancer 1Infiltrating Bladder Urothelial Carcinoma 1Immunoblastic Lymphadenopathy 1Hypoxia 1Gallbladder Neoplasms 1Cholangiocarcinoma 1

Interventions

transplatin 1Platinum 1Gemcitabine 1Cystectomy 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Infiltrating Bladder Urothelial Carcinoma × Gemcitabine × Clear all
NCT02944357 2017-11-17

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Mayo Clinic

Phase NA Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡